Clarity

C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market

Retrieved on: 
金曜日, 4月 26, 2024
Research, Managed Care, Pharmaceutical, Consumer, Mental Health, Health Technology, Clinical Trials, Science, Biotechnology, Neurology, Seniors, Health, Epidemiology, Biogen, Brain, Protein, Learning, Donanemab, Clarity, Prognosis, Partnership, PET, Pathology, Non-fungible token, Dementia, Alzheimer's disease, Hoshiko Yamane, DSM-IV codes, Peptide, Diagnosis, Biomarker, Ageing, Clinical trial, Medical imaging

Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialization aspects of the field.

Key Points: 
  • Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialization aspects of the field.
  • Other research has found that Japan has the highest proportion of people with dementia of any country.
  • We believe our partnership with Mediford Corporation will unlock many opportunities and possibilities.
  • Mediford Corporation is known for providing clinical and non-clinical analysis that supports each stage of drug research and development, including advanced treatment options.

Perceptyx Announces Winners of 2024 EX IMPACT Awards

Retrieved on: 
木曜日, 4月 4, 2024
RN, ESAB, Organization, Align Technology, Align, Talent management, Continual improvement process, Communication, EX, Partnership, Carhartt, Change management, Orthodontics, Intranet, UC, Acquisition, UC San Diego Health, Morale, Trust, Safety, Workforce, Workplace, Clarity, DEI, Nursing

TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.

Key Points: 
  • TEMECULA, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Perceptyx , the global leader in employee experience (EX) transformation, today announced the winners of its inaugural EX IMPACT Awards, which honor the ways companies discovered insights, acted on results, and impacted their employees’ experience using Perceptyx’s People Insights Platform.
  • The EX IMPACT Awards recognize people-first organizations making a difference in workplace culture.
  • “The EX IMPACT Awards recognize organizations that use the Perceptyx People Insights Platform to improve their employees’ experience,” said Kirsten Helvey, Chief Customer Officer at Perceptyx.
  • “This EX Impact Award showcases the potential this type of strategy carries not only for our organization but others as well!”

Without the use of third-party auditors in carbon reporting, companies report lower, but unreliable, emissions

Retrieved on: 
火曜日, 3月 26, 2024
Organization, Science Based Targets initiative, ESG, Research, Science, AI, Security (finance), Carbon, CO2, Clarity, Cryptocurrency

Companies that do engage third-party auditors, while they may show higher current emissions, take actionable steps to reduce their future carbon emissions.

Key Points: 
  • Companies that do engage third-party auditors, while they may show higher current emissions, take actionable steps to reduce their future carbon emissions.
  • As opposed to those who do not audit their emissions, companies that provide accurate emissions reporting actively set appropriate targets and reduce their future emissions.
  • “It makes sense to also include smaller companies in the scope of companies that need to obtain assurance for their carbon emissions.
  • Without accurately reported data from all companies, working to reduce carbon emissions will forever be an impossible hurdle,” concluded Berg.

BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress

Retrieved on: 
月曜日, 3月 11, 2024
Diagnosis, Brain, Conference, Lecanemab, Disease, Incidence, Alpha-synuclein, Eisai, Patient, CAA, ARIA, DSM-IV codes, Antibody, Safety, Clarity, Pharmaceutical industry

BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.

Key Points: 
  • BioArctic's founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta (Aβ) antibody lecanemab and other anti Aβ antibodies.
  • Lecanemab was designed to preferentially bind soluble (protofibrils), as well as insoluble Aβ aggregates (fibrils), to reduce both Aβ protofibrils and Aβ plaques in the brain.
  • The difference in binding to CAA[1] was presented, with lecanemab having lower binding to CAA than most other antibodies.
  • This could explain the difference in the adverse event ARIA[2] seen between different antibodies, with lecanemab showing relatively low incidence of ARIA.

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
月曜日, 3月 4, 2024
OGA, Research, BIIB, Investment, Eisai, Alpha-synuclein, Amyloid, Conference, Biogen, Quantitative systems pharmacology, Dementia, MCI, QSP, Clarity, MAPT, Brain, Vaccine

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Retrieved on: 
木曜日, 2月 29, 2024
Lecanemab, Novel, Eisai, Conference, DSM-IV codes, Trial of the century, Clarity, Brain

In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.

Key Points: 
  • In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.
  • At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies.
  • In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.
  • Lecanemab for the treatment of early Alzheimer's disease: the extension of efficacy results from Clarity AD

BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress

Retrieved on: 
木曜日, 2月 29, 2024
AB, Lecanemab, Novel, Eisai, Conference, DSM-IV codes, Trial of the century, Clarity, Brain

In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.

Key Points: 
  • In total, lecanemab will be featured in six presentations, including an oral presentation by BioArctic's founder Professor Lars Lannfelt.
  • At AD/PD, BioArctic will present one oral presentation and one poster on lecanemab, both focused on the binding properties of lecanemab to various types of Aβ of lecanemab compared to several other Aβ antibodies.
  • In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented.
  • Lecanemab for the treatment of early Alzheimer's disease: the extension of efficacy results from Clarity AD

Revyrie acquires Myntr to expand upon the venture studio's e-commerce capabilities

Retrieved on: 
水曜日, 1月 17, 2024
Culture, Acquisition, Clarity, Digital, Retail

Revyrie acquires Myntr in all cash deal, expanding e-commerce capabilities and strengthening digital portfolio.

Key Points: 
  • Revyrie acquires Myntr in all cash deal, expanding e-commerce capabilities and strengthening digital portfolio.
  • This acquisition bolsters Revyrie's Digital Commerce portfolio and expands its delivery footprint as a leading provider of retail services and solutions.
  • Founded by Dan Faiman, Revyrie leverages its global resources to help launch and incubate cutting edge brands and technologies.
  • "We are thrilled to welcome Myntr along with their valued customers and partners to Revyrie.

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China

Retrieved on: 
水曜日, 1月 10, 2024
BIIB, Patient, MCI, Insurance, Alzheimer's disease, Lecanemab, Biogen, Biomarker, Marketing, Brain, Ageing, Clarity

Preparations for launch within the second quarter of Eisai's FY 2024 (July 1 - September 30, 2024) are underway.

Key Points: 
  • Preparations for launch within the second quarter of Eisai's FY 2024 (July 1 - September 30, 2024) are underway.
  • LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • China is the third country to grant marketing approval, following the traditional approval in the U.S. in July 2023 and Japanese approval in September 2023.
  • ** An online business of Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, a joint venture company with JD Health.

Leqembi® approved for the treatment of Alzheimer's disease in China

Retrieved on: 
火曜日, 1月 9, 2024
Patient, MCI, Insurance, Memory, Eisai, Lecanemab, Biomarker, Marketing, Brain, Ageing, Clarity, Pharmaceutical industry

China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.

Key Points: 
  • China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023.
  • Leqembi is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
  • Eisai will distribute the product in China and will conduct information provision activities through specialized Medical Representatives.
  • Dosage and administration: The usual dose of lecanemab (recombinant) is 10mg/kg infused intravenously over approximately 1 hour, once every 2 weeks.